OneDigital Investment Advisors LLC Takes $1.27 Million Position in Edwards Lifesciences Corporation $EW

Key Points

• OneDigital Investment Advisors initiated a $1.27 million position in Edwards Lifesciences during the second quarter. Institutional investors collectively own approximately 79.46% of the company.
• Analysts maintain a positive outlook, with 17 Buy ratings and six Holds producing a consensus “Moderate Buy” rating and an average price target of $100.27.
• Edwards reported quarterly EPS of $0.78, beating estimates by $0.04, while revenue rose 13.6% year over year to $1.74 billion. The stock opened at $90.84, and insiders sold roughly $2.22 million of shares over the past quarter.

OneDigital Investment Advisors LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 14,060 shares of the medical research company's stock, valued at approximately $1,272,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. Bank of New York Mellon Corp purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $1,274,082,000. Norges Bank purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the period. Viking Global Investors LP acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at $238,688,000. Finally, Marshall Wace LLP grew its holdings in Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company's stock valued at $505,160,000 after purchasing an additional 2,359,128 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. BTIG Research raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Truist Financial lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. Citigroup boosted their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Finally, Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a "hold" rating in a report on Friday, April 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $90.84 on Tuesday. The firm has a fifty day moving average of $88.83 and a two-hundred day moving average of $84.43. The firm has a market cap of $52.31 billion, a P/E ratio of 52.21, a P/E/G ratio of 2.30 and a beta of 0.85. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the business posted $0.67 EPS. The company's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company's stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,570 shares of company stock worth $2,219,390 over the last quarter. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source